Long noncoding RNAs (LncRNA), a class of transcripts with lengths >200 nt, play a master role in the regulation of cancer pathogenesis. Recently, the CRISPR-Cas9 system has been explored as a revolutionary genome editing tool for molecular biology. Growing evidence shows that LncRNAs can be targeted by the CRISPR-Cas9 system used for evaluating its function. Thus, the CRISPR-Cas9 systems provide a novel gene-editing strategy for the modification of LncRNA expression. This review summarizes current knowledge of the functions and underlying mechanisms of LncRNA by CRISPR-Cas9. Emerging strategies for non-viral/viral delivery of CRISPR-Cas9 in a clinical context are also discussed.
Get full access to this article
View all access options for this article.
References
1.
LiHJ, SunXM, LiZK, et al.LncRNA UCA1 promotes mitochondrial function of bladder cancer via the mir-195/ARL2 signaling pathway. Cell Physiol Biochem, 2017; 43:2548–2561.
2.
HirotaK, MiyoshiT, KugouK, et al.Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs. Nature, 2008; 456:130–134.
3.
MarinerPD, WaltersRD, EspinozaCA, et al.Human Alu RNA is a modular transacting repressor of mRNA transcription during heat shock. Mol Cell, 2008; 29:499–509.
4.
KunejT, GodnicI, HorvatSet al. Cross talk between microRNA and coding cancer genes. Cancer J, 2012; 18:223–231.
5.
LeeYS, DuttaA. MicroRNAs in cancer. Annu Rev Pathol, 2009; 4:199–227.
6.
HaTY. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw, 2011; 11:125–154.
7.
GuemetA, GrumolatoL. CRISPR/Cas9 editing of the genome for cancer modeling. Methods, 2017; 121–122:130–137.
8.
GajT, GersbachCA, BarbasCF. ZFN, TALEN, and CRISPR/Cas based methods for genome engineering. Trends Biotechnol, 2013; 31:397–405.
9.
HorvathP, BarrangouB. CRISPR/Cas, the immune system of bacteria and archaea. Science, 2010; 327:167–170.
10.
WiedenheftB, SternbergSH, DoudnaJA. RNA-guided genetic silencing systems in bacteria and archaea. Nature, 2012; 482:331–338.
11.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337:816–821.
12.
AndersC, NiewoehnerO, DuerstA, et al.Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature, 2014; 513:569–573.
13.
SanderJD, JoungJK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol, 2014; 32:347–355.
14.
RanFA, HsuPD, WrightJ, et al.Genome engineering using the CRISPR/Cas9 system. Nat Protoc, 2013; 8:2281–2308.
15.
ShaoM, XuTR, ChenCS. The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models. Dongwuxue Yanjiu, 2016; 37:191–204.
16.
WangT, WeiJJ, SabatiniDM, et al.Genetic screens in human cells using the CRISPR-Cas9 system. Science, 2014; 343:80–84.
17.
MaederML, GersbachCA. Genome-editing technologies for gene and cell therapy. Mol Ther, 2016; 24:430–446.
18.
Durruthy-DurruthyJ, SebastianoV, WossidloM, et al.The primate-specific noncoding RNA HPAT5 regulates pluripotency during human preimplantation development and nuclear reprogramming. Nat Genet, 2016; 48:44–52.
19.
ZhuS, LiW, LiuJ. Genome-scale deletion screening of human long noncoding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol, 2016; 34:1279–1286.
20.
BassettAR, AkhtarA, BarlowDP. Considerations when investigating lncRNA function in vivo. Elife, 2014; 3:e03058.
21.
ParalkarVR, TabordaCC, HuangP, et al.Unlinking an lncRNA from its associated cis element. Mol Cell, 2016; 62:104–110.
22.
YinY, YanP, LuJ, et al.Opposing roles for the lncRNA haunt and its genomic locus in regulating HOXA gene activation during embryonic stem cell differentiation. Cell Stem Cell, 2015; 16:504–516.
23.
LiuY, HanX, YuanJ, et al.Biallelic insertion of a transcriptional terminator via the CRISPR/Cas9 system efficiently silences expression of protein-coding and noncoding RNA genes. J Biol Chem, 2017; 292:5624–5633.
24.
PefanisE, WangJ, RothschildG, et al.RNA exosome-regulated long noncoding RNA transcription controls super-enhancer activity. Cell, 2015; 161:774–789.
25.
Aparicio-PratE, ArnanC, SalaI, et al.DECKO: single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs. BMC Genomics, 2015; 16:846.
26.
ZhuZR, GonzalezF, HuangfuD. The iCRISPR platform for rapid genome editing in human pluripotent stem cells. Methods Enzymol, 2014; 546:215–250.
27.
PengWX, HuangJG, YangL, et al.Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer, 2017; 16:161.
28.
SinghR, GuptaSC, PengWX, et al.Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis, 2016; 7:e2262.
29.
KoiralaP, HuangJ, HoTT, et al.LncRNA AK023948 is a positive regulator of AKT. Nat Commun, 2017; 8:14422.
30.
HoTT, ZhouN, HuangJ, et al.Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res, 2015; 43:e17.
31.
ZhenS, HuaL, LiuYH, et al.Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer. Oncotarget, 2017; 8:9634–9646.
32.
LiJ, ZhangZ, XiongL, et al.SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. Biochem Biophys Res Commun, 2017; 487:146–152.
33.
DuZ, SunT, HacisuleymanE, et al.Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun, 2016; 7:10982.
34.
BeaverLM, KuintzleR, BuchananA, et al.Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. J Nutr Biochem, 2017; 42:72–83.
35.
YuY, Nangia-MakkerP, FarhanaL, et al.A novel mechanism of LncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer, 2017; 16:155.
36.
LiuJ, BenQ, LuE, et al.Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer. Cell Death Dis, 2018; 9:168.
37.
Chaverra-RodriguezD, MaciasVM, HughesGL, et al.Targeted delivery of CRISPR-Cas9 ribonucleoprotein into arthropod ovaries for heritable germline gene editing. Nat Commun, 2018; 9:3008.
38.
BarrangouR, BirminghamA, WiemannS, et al.Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res, 2015; 43:3407–3419.
39.
ShenB, ZhangW, ZhangJ, et al.Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods, 2014; 11:399–402.
40.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science, 2013; 339:819–823.
41.
FuY, SanderJD, ReyonD, et al.Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol, 2014; 32:279–284.
42.
SlaymakerIM, GaoL, ZetscheB, et al.Rationally engineered Cas9 nucleases with improved specificity. Science, 2016; 351:84–88.
43.
KleinstiverBP, PattanayakV, PrewMS, et al.High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide offtarget effects. Nature, 2016; 529:490–495.
44.
ChiraS, GuleiD, HajitouA, et al.CRISPR/Cas9: transcending the reality of genome editing. Mol Ther Nucleic Acids, 2017; 7:211–222.
45.
ZhenS, HuaL, LiuYH, et al.Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther, 2015; 22:404–412.
46.
LeeCM, CradickTJ, FineEJ, et al.Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing. Mol Ther, 2016; 24:475–487.
47.
XuL, ZhaoL, GaoY, XuJ, et al.Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res, 2017; 45:e28.
48.
Aquino-JarquinG, Toscano-GaribayJD. RNA aptamer evolution: two decades of SELEction. Int J Mol Sci, 2011; 12:9155–9171.
49.
ZhenS, TakahashiY, NaritaS, et al.Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget, 2017; 8:9375–9387.
50.
MoutR, RayM, Yesilbag TongaG, et al.Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing. ACS Nano, 2017; 11:2452–2458.
51.
KouranovaE, ForbesK, ZhaoG. CRISPRs for optimal targeting: delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos. Hum Gene Ther, 2016; 27:464–475.
52.
WilliamsMR, Fricano-KuglerCJ, GetzSA. A retroviral CRISPR-Cas9 system for cellular autism-associated phenotype discovery in developing neurons. Sci Rep, 2016; 6:25611.
53.
Koike-YusaH, LiY, TanEP, et al.Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol, 2014; 32:267–273.
54.
WangD, MouH, LiS. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther, 2015; 26:432–442.
55.
SwiechL, HeidenreichM, BanerjeeA. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol, 2015; 33:102–106.
DowLE. Modeling disease in vivo with CRISPR/Cas9. Trends Mol Med, 2015; 21:609–621.
58.
de SolisCA, HoA, HolehonnurR, et al.The development of a viral mediated CRISPR/Cas9 system with doxycycline dependent gRNA expression for inducible in vitro and in vivo genome editing. Front Mol Neurosci, 2016; 9:70.
59.
LiuKI, RamliMN, WooCW, et al.A chemical inducible CRISPR-Cas9 system for rapid control of genome editing. Nat Chem Biol, 2016; 12:980–987.
60.
HirosawaM, FujitaY, ParrCJC, et al.Cell type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. Nucleic Acids Res, 2017; 45:e118.
61.
NelsonCE, GersbachCA. Engineering delivery vehicles for genome editing. Annu Rev Chem Biomol Eng, 2016; 7:637–662.
